Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms.
作者信息
Polverelli N, Catani L, Vianelli N, Baccarani M, Cavo M, Palandri F
机构信息
Department of Specialistic, Diagnostic and Experimental Medicine, Institute of Hematology "L. and A. Seràgnoli", St Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy.
出版信息
Ann Hematol. 2015 Sep;94(9):1585-7. doi: 10.1007/s00277-015-2397-9. Epub 2015 May 16.
PMID:25975976
Abstract
摘要
Zotero 插件